Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors

A technology of phosphatase inhibitor and composition, applied in the field of ophthalmic composition, can solve the problems of difficulty in target tissue, limitation of treatment of posterior segment diseases, etc.
CN101918019BActive Publication Date: 2014-11-26AURINIA PHARMA
8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
AURINIA PHARMA
Publication Date
2014-11-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and / or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.
Need to check novelty before this filing date? Find Prior Art

Description

field of invention

[0001] Embodiments disclosed herein relate to stable ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly, to methods of treating ocular diseases and / or disorders using the disclosed compositions. Background technique

[0002] Diseases and injuries of the anterior surface of the eye are the leading cause of visits to physicians for ophthalmic medical care in the United States. These diseases and injuries are among the most painful eye conditions and can lead to disability and blindness. Major clinical problems of the ocular surface include ocular surface dryness, tear film abnormalities, and associated complications; ocular surface trauma leading to morbidity and scarring; corneal dysfunction dystrophy and genetic disorders; inflammatory disorders; and External ocular infections. Eye diseases and injuries can range from itching, runny eyes to impaired vision. Therefore, it is important to address eye proble...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More